BR112012014558B8 - nova composição de hidrogel transdérmico de dexibuprofeno - Google Patents

nova composição de hidrogel transdérmico de dexibuprofeno

Info

Publication number
BR112012014558B8
BR112012014558B8 BR112012014558A BR112012014558A BR112012014558B8 BR 112012014558 B8 BR112012014558 B8 BR 112012014558B8 BR 112012014558 A BR112012014558 A BR 112012014558A BR 112012014558 A BR112012014558 A BR 112012014558A BR 112012014558 B8 BR112012014558 B8 BR 112012014558B8
Authority
BR
Brazil
Prior art keywords
dexibuprofen
hydrogel
new
prepared
transdermal hydrogel
Prior art date
Application number
BR112012014558A
Other languages
English (en)
Other versions
BR112012014558B1 (pt
BR112012014558A2 (pt
BR112012014558A8 (pt
Inventor
Vel Palanisamy Anandsenthil
Stuart Bergman Jeffrey
Devarajan Sampathkumar
Ramalingam Selvakumar
Original Assignee
Shasun Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shasun Pharmaceuticals Ltd filed Critical Shasun Pharmaceuticals Ltd
Publication of BR112012014558A2 publication Critical patent/BR112012014558A2/pt
Publication of BR112012014558A8 publication Critical patent/BR112012014558A8/pt
Publication of BR112012014558B1 publication Critical patent/BR112012014558B1/pt
Publication of BR112012014558B8 publication Critical patent/BR112012014558B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

nova composição de hidrogel transdérmico de dexibuprofeno um hidrogel transdérmico não alcoólico de dexibuprofeno estável foi preparado pela utilização de um processo de manufatura simples, e os ensaios experimentais mostraram que o agente modificador de ph, antioxidante e solvente miscível em água são os excipientes essenciais para se obter o hidrogel transdérmico não alcoólico de dexibuprofeno estável. o hidrogel de dexibuprofeno preparado utilizando carbopol como um polímero gelificante produziu um gel opaco, enquanto que o hidrogel preparado utilizando-se hiroxipropil metilcelulose (hpmc) como um polímero gelificante produziu um gel transparente. não houve quaisquer alterações significativas no que diz respeito à descrição física, ph, ensaio e particularmente aos valores das substâncias relativa quando os hidrogéis foram submetidos ao estudo de estabilidade em condição acelerada (40°c/75% de ur) por 3 meses em tubos laminados.
BR112012014558A 2009-12-16 2010-12-09 nova composição de hidrogel transdérmico de dexibuprofeno BR112012014558B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3121/CHE/2009 2009-12-16
IN3121CH2009 2009-12-16
PCT/IN2010/000795 WO2011073998A1 (en) 2009-12-16 2010-12-09 Composition of dexibuprofen transdermal hydrogel

Publications (4)

Publication Number Publication Date
BR112012014558A2 BR112012014558A2 (pt) 2017-12-19
BR112012014558A8 BR112012014558A8 (pt) 2018-04-10
BR112012014558B1 BR112012014558B1 (pt) 2021-02-02
BR112012014558B8 true BR112012014558B8 (pt) 2021-05-25

Family

ID=54200209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014558A BR112012014558B8 (pt) 2009-12-16 2010-12-09 nova composição de hidrogel transdérmico de dexibuprofeno

Country Status (15)

Country Link
US (2) US20120259018A1 (pt)
EP (1) EP2512446B1 (pt)
JP (1) JP2013514347A (pt)
KR (1) KR101884951B1 (pt)
CN (1) CN102665681A (pt)
AU (1) AU2010331761B2 (pt)
BR (1) BR112012014558B8 (pt)
CA (1) CA2784827C (pt)
DK (1) DK2512446T3 (pt)
ES (1) ES2541483T3 (pt)
MX (1) MX352187B (pt)
PE (1) PE20130245A1 (pt)
PL (1) PL2512446T3 (pt)
RU (1) RU2012129527A (pt)
WO (1) WO2011073998A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101894891B1 (ko) * 2012-11-30 2018-09-04 동아에스티주식회사 흡수가 증가된 덱시부프로펜 에멀젼 함유 겔 제형
KR102210032B1 (ko) * 2013-01-17 2021-02-02 가부시키가이샤 카나에테크노스 외용 첩부제
CA2900597C (en) * 2013-02-14 2021-11-02 Sanofi Chewable composition for oral administration and process for preparing thereof
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
JP6513667B2 (ja) 2013-08-08 2019-05-15 ノヴァン，インコーポレイテッド 局所用組成物およびそれを使用する方法
WO2016022170A1 (en) 2014-08-08 2016-02-11 Novan, Inc. Topical emulsions
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016007834A1 (en) 2014-07-11 2016-01-14 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016028834A1 (en) 2014-08-20 2016-02-25 3M Innovative Properties Company Devices and methods for sample partitioning and analysis
BR112017003130A2 (pt) * 2014-08-20 2017-11-28 3M Innovative Properties Co dispositivo e método de cultura anaeróbica autocontido para micro-organismos redutores de sulfato
CN104188899A (zh) * 2014-09-26 2014-12-10 天津市聚星康华医药科技有限公司 一种洛索洛芬钠凝胶及其制备方法
CN105168117B (zh) * 2015-10-04 2018-08-07 临沂大学 一种右旋布洛芬微乳凝胶及其制备方法
KR102319497B1 (ko) 2016-03-02 2021-11-01 노반, 인크. 염증 치료용 조성물 및 염증 치료 방법
CN105935445B (zh) * 2016-03-28 2019-02-01 赤峰赛林泰药业有限公司 含2-(-4-异丁基苯基)丙酸右旋物的药物组合物及其制备方法
KR102426006B1 (ko) 2016-04-13 2022-07-29 노반, 인크. 감염 치료용 조성물, 시스템, 키트, 및 방법
CN106074459A (zh) * 2016-07-11 2016-11-09 雷春生 一种持久保水型水凝胶贴支持层材料的制备方法
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
CN109432061B (zh) * 2018-11-09 2020-10-30 北京德默高科医药技术有限公司 含有布洛芬或其结构类似物的多层经皮给药系统
CN111388409B (zh) * 2020-03-25 2023-01-31 牡丹江医学院 一种皮肤止痒抑菌贴剂用水凝胶材料的制备方法
US11844753B2 (en) 2021-11-08 2023-12-19 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient
KR102419076B1 (ko) * 2022-01-17 2022-07-08 장보경 마취제 조성물 및 이의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
DE4024801A1 (de) * 1990-08-04 1992-02-06 Porsche Ag Abgasanlage einer brennkraftmaschine
GEP20002013B (en) * 1991-05-13 2000-04-10 Boots Co Plc Therapeutical Means
PL314036A1 (en) * 1993-10-20 1996-08-05 Boots Co Plc Pharmaceutical composition
AT408067B (de) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
ATE239068T1 (de) * 1995-06-07 2003-05-15 Lee County Mosquito Control Di Schmiermittelzusammensetzungen und verfahren
US20010023261A1 (en) * 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
AU3212199A (en) * 1998-03-31 1999-10-18 Scimed Life Systems, Inc. Temperature controlled solute delivery system
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE19945522A1 (de) * 1999-09-23 2001-04-05 Hexal Ag Pharmazeutisches, wirkstoffhaltiges Gel
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
EP1390085B1 (en) * 2001-05-01 2009-08-05 A.V. Topchiev Institute of Petrochemical Synthesis Hydrogel compositions
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
PE20040321A1 (es) * 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US7052715B2 (en) * 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
WO2004110511A1 (en) * 2003-06-19 2004-12-23 Coloplast A/S A wound care device
UY28398A1 (es) * 2003-07-02 2004-11-08 Alza Corp Método y parche de inmunización por disposición de microproyección
CH715855B1 (de) * 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
JP4128521B2 (ja) * 2003-12-19 2008-07-30 信越化学工業株式会社 ゲル状シート及びその製造方法
WO2006122183A2 (en) * 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
JP4969812B2 (ja) * 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
WO2007041526A2 (en) * 2005-09-30 2007-04-12 Transcutaneous Technologies Inc. Iontophoresis apparatus and method to deliver antibiotics to biological interfaces
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
CN101455654B (zh) * 2007-12-13 2013-03-06 天津医科大学 精氨酸布洛芬凝胶剂及其制备方法
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
BRPI0918142A2 (pt) * 2008-09-10 2015-12-01 Biochemics Inc composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico

Also Published As

Publication number Publication date
AU2010331761B2 (en) 2015-09-24
CN102665681A (zh) 2012-09-12
US20150342879A1 (en) 2015-12-03
EP2512446A4 (en) 2012-10-24
MX352187B (es) 2017-11-13
KR20120092700A (ko) 2012-08-21
US20120259018A1 (en) 2012-10-11
EP2512446B1 (en) 2015-04-08
ES2541483T3 (es) 2015-07-21
BR112012014558B1 (pt) 2021-02-02
AU2010331761A1 (en) 2012-07-12
PL2512446T3 (pl) 2015-08-31
RU2012129527A (ru) 2014-01-27
WO2011073998A1 (en) 2011-06-23
CA2784827C (en) 2018-10-23
US10085939B2 (en) 2018-10-02
EP2512446A1 (en) 2012-10-24
CA2784827A1 (en) 2011-06-23
KR101884951B1 (ko) 2018-08-02
DK2512446T3 (en) 2015-06-29
PE20130245A1 (es) 2013-03-08
JP2013514347A (ja) 2013-04-25
MX2012007062A (es) 2012-10-03
BR112012014558A2 (pt) 2017-12-19
BR112012014558A8 (pt) 2018-04-10

Similar Documents

Publication Publication Date Title
BR112012014558B8 (pt) nova composição de hidrogel transdérmico de dexibuprofeno
BR112016023368A8 (pt) composição de catalisador, método de preparação da mesma, produto de carbono poroso moldado, método de preparação do mesmo e processo para a conversão catalítica de um reagente
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
BR112017022045A2 (pt) composição e kits para matrizes de microgel pseudoplástico
CL2011003091A1 (es) Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion.
BR112012007373A2 (pt) lentes de contato de hidrogel de silicone e métodos para a fabricação de lentes de contato de hidrogel de silicone
BRPI1003281A2 (pt) Composição e método para maquilar um substrato queratínico
BR112018014026A2 (pt) composição líquida compreendendo um polímero múltiplas fases, seu método de preparação e uso
BR112015021709B8 (pt) Poli(beta-amino ésteres) modificados para administração de fármacos e nanopartícula compreendendo os mesmos, uma composição compreendendo os mesmos, método de encapsulamento de um agente em uma matriz de polímeros para formar nanopartículas, e uso dos poli(beta-amino ésteres)
BRPI0923871B8 (pt) compostos dipirrometenos substituídos por boro fluorescentes e uso dos mesmos para diagnósticos
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
BR112013001226A2 (pt) pasta para impressão por transferência frio, corante para impressão e método para preparação dos mesmos
BR112018012808A2 (pt) polímero de emulsão, e, composição.
BR112014027753A2 (pt) métodos e aparelhos para identificar um protocolo de comunicação sendo usado em um sistema de controle de processo
BR112017006533A2 (pt) usos de trealose em suspensões celulares
BR112018014029A2 (pt) composição líquida compreendendo um polímero múltiplas fases e um monômero (met) acrílico, seu método de preparação e uso
BR112017023722A2 (pt) composição formadora de película curável, substrato revestido e método para revestir um substrato
BR112018006492A2 (pt) composição, artigo fabricado, processo para preparar
PE20150932A1 (es) Proceso para mejorar las propiedades reologicas de una dispersion acuosa
ATE514746T1 (de) Kohlenstoffnanoröhrchen verstärkte polymerzusammensetzung und verfahren zu deren herstellung
BR112012027035A2 (pt) método, dispositivo e sistema para comunicação entre unidades de processamento central duplas
BR112018009839A8 (pt) método para cimentar revestimento em um furo de poço e sistema para cimentar revestimento em um furo de poço
BR102015003197A8 (pt) processo de produção em escala de hidrogel de celulose bacteriana purificada obtida pela polimerização da glicose a partir de açúcares de fontes renováveis via biotecnologia por meio da propagação de bactérias produtoras de celulose particularmente gluconoacetobacter hansenii lmspe, em reatores para aplicação nas áreas de saúde, farmacotécnica e cosmiatria
BR112019007865A2 (pt) método para processamento de produtos de amplificação do círculo rolante
CO6630116A2 (es) Composición de dexibuprofeno e hidrogel transdèrmico novedosa composición de dexibuprofeno en hidrogel transdérmica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.